InvestSMART

PYC Therapeutics Limited (ASX: PYC) - Announcements

- Current share price for PYC : $2.910

ASX company news and announcements for PYC Therapeutics Limited (PYC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PYC Therapeutics Limited (PYC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PYC Therapeutics Limited (PYC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PYC Therapeutics Limited (PYC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,862 PKD - First Patient Dosed in OLE Study 11 Sep 2026 8:25AM $2.320 $2.910 risen by 25.43%
$2,862 S&P DJI Announces September 2026 Quarterly Rebalance 4 Sep 2026 5:10PM $2.490 $2.910 risen by 16.87%
$2,862 Investor Webinar Presentation Q3 2026 4 Sep 2026 8:30AM $2.570 $2.910 risen by 13.23%
$2,862 ADOA Program - Data Presentation 3 Sep 2026 8:21AM $2.430 $2.910 risen by 19.75%
$2,862 Ceasing to be a substantial holder 2 Sep 2026 3:52PM $2.405 $2.910 risen by 21%
$2,862 PKD - Presentation of Clinical Safety Data 31 Aug 2026 8:10AM $2.250 $2.910 risen by 29.33%
$2,862 2026 Corporate Governance Statement 28 Aug 2026 7:14PM $2.250 $2.910 risen by 29.33%
$2,862 Appendix 4G 28 Aug 2026 7:12PM $2.250 $2.910 risen by 29.33%
$2,862 2026 Annual Report to Shareholders 28 Aug 2026 7:11PM $2.250 $2.910 risen by 29.33%
$2,862 Appendix 4E 28 Aug 2026 7:08PM $2.250 $2.910 risen by 29.33%
$2,862 Notification regarding unquoted securities - PYC 26 Aug 2026 4:54PM $2.170 $2.910 risen by 34.10%
$2,862 Investor Webinar 18 Aug 2026 8:16AM $2.130 $2.910 risen by 36.62%
$2,862 Change of Director's Interest Notice 14 Aug 2026 11:02AM $2.130 $2.910 risen by 36.62%
$2,862 Notification regarding unquoted securities - PYC 13 Aug 2026 2:42PM $2.110 $2.910 risen by 37.91%
$2,862 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jul 2026 8:45AM $1.625 $2.910 risen by 79.08%
$2,862 PKD - Safety Committee Approves Dose Escalation 22 Jul 2026 8:20AM $1.625 $2.910 risen by 79.08%
$2,862 ADOA Program Update 21 Jul 2026 8:32AM $1.615 $2.910 risen by 80.19%
$2,862 Notification of cessation of securities - PYC 20 Jul 2026 7:03PM $1.615 $2.910 risen by 80.19%
$2,862 Presentation At 2026 PMS Foundation Family Conference 20 Jul 2026 8:28AM $1.610 $2.910 risen by 80.75%
$2,862 Results of Meeting 15 Jul 2026 6:12PM $1.615 $2.910 risen by 80.19%
$2,862 Grant of Patents by the US Patent Office 8 Jul 2026 9:01AM $1.535 $2.910 risen by 89.58%
$2,862 Appointment of Chief Financial Officer 7 Jul 2026 8:21AM $1.555 $2.910 risen by 87.14%
$2,862 Notification of cessation of securities - PYC 18 Jun 2026 8:26AM $1.335 $2.910 risen by 117.98%
$2,862 Becoming a substantial holder 16 Jun 2026 4:29PM $1.270 $2.910 risen by 129.13%
$2,862 Company Secretary Appointment/Resignation 15 Jun 2026 3:01PM $1.225 $2.910 risen by 137.55%

1 - 25 of 943 results

Page 1 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.